- Syphilis immunoassay diagnostics are crucial tools used for the detection and diagnosis of syphilis, an increasingly prevalent sexually transmitted infection (STI). These tests provide accurate results and are essential for early diagnosis and treatment to prevent further complications
- The demand for syphilis immunoassay diagnostics is significantly driven by the rising global prevalence of syphilis and other sexually transmitted infections (STIs), as well as advancements in diagnostic technologies. In addition, the growing focus on early detection, public health initiatives, and improving access to healthcare contribute to the increasing adoption of these diagnostic tools
- North America is expected to dominate the syphilis immunoassay diagnostics market with a market share of 42.6% globally. The region’s dominance is attributed to its advanced healthcare infrastructure, high adoption of innovative diagnostic technologies, and strong market presence of key players
- Asia-Pacific is expected to be the fastest growing region in the syphilis immunoassay diagnostics market with market share of 17.3% in the syphilis immunoassay diagnostics market, driven by factors such as expanding healthcare infrastructure, increasing awareness about sexually transmitted infections, and government-led public health initiatives
- The chemiluminescence immunoassays (CLIA) technology segment is expected to dominate the syphilis immunoassay diagnostics market with the largest share of 45.3% due to its high sensitivity, rapid detection capabilities, and suitability for automation in clinical settings, driving its increased adoption for syphilis testing in diagnostic labs
